share_log

金斯瑞生物科技：海外監管公告：上市附屬公司傳奇生物科技股份有限公司截至二零二四年三月三十一日止第一季度的未經審核財務業績

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 31 MARCH 2024 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION

Hong Kong Stock Exchange ·  May 13 07:30
Summary by Moomoo AI
傳奇生物科技於2024年5月13日公佈2024年第一季度未經審計財務業績，顯示許可收入為1,220萬美元，合作收入為7,850萬美元，合作成本收入為4,910萬美元。研發開支為1.010億美元，行政開支為3,190萬美元，銷售及分銷開支為2,420萬美元。淨虧損為5,980萬美元。截至2024年3月31日，現金及現金等價物、定期存款和短期投資總額為13億美元。公司在報告期間取得進展，包括CARVYKTI®在美國、歐洲和巴西的適應症擴大，以及與諾華製藥公司簽訂主生產及供應服務協議。傳奇生物預計2026年實現營業利潤。
傳奇生物科技於2024年5月13日公佈2024年第一季度未經審計財務業績，顯示許可收入為1,220萬美元，合作收入為7,850萬美元，合作成本收入為4,910萬美元。研發開支為1.010億美元，行政開支為3,190萬美元，銷售及分銷開支為2,420萬美元。淨虧損為5,980萬美元。截至2024年3月31日，現金及現金等價物、定期存款和短期投資總額為13億美元。公司在報告期間取得進展，包括CARVYKTI®在美國、歐洲和巴西的適應症擴大，以及與諾華製藥公司簽訂主生產及供應服務協議。傳奇生物預計2026年實現營業利潤。
Legendary Biotechnology announced its first quarter 2024 unaudited financial results on May 13, 2024, showing license revenue of $1,220 million, cooperative revenue of $7,850 million, and cooperative cost revenue of $4.9 million. R&D expenses were US$1,010 million, administrative expenses were US$3,190 million, and sales and distribution expenses were US$2,420 million. Net loss was $5,980 million. As of March 31, 2024, cash and cash equivalents, term deposits and short-term investments totaled US$13 billion. THE COMPANY ACHIEVED PROGRESS DURING THE REPORTING PERIOD, INCLUDING THE EXPANSION OF CARVYKTI® PRESCRIPTIONS IN THE UNITED STATES, EUROPE AND BRAZIL, AND THE SIGNING OF A MASTER PRODUCTION AND SUPPLY SERVICE AGREEMENT WITH NOVARA PHARMACEUTICALS. Legendary Bio expects to achieve an operating profit in 2026.
Legendary Biotechnology announced its first quarter 2024 unaudited financial results on May 13, 2024, showing license revenue of $1,220 million, cooperative revenue of $7,850 million, and cooperative cost revenue of $4.9 million. R&D expenses were US$1,010 million, administrative expenses were US$3,190 million, and sales and distribution expenses were US$2,420 million. Net loss was $5,980 million. As of March 31, 2024, cash and cash equivalents, term deposits and short-term investments totaled US$13 billion. THE COMPANY ACHIEVED PROGRESS DURING THE REPORTING PERIOD, INCLUDING THE EXPANSION OF CARVYKTI® PRESCRIPTIONS IN THE UNITED STATES, EUROPE AND BRAZIL, AND THE SIGNING OF A MASTER PRODUCTION AND SUPPLY SERVICE AGREEMENT WITH NOVARA PHARMACEUTICALS. Legendary Bio expects to achieve an operating profit in 2026.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more